Eastwood Bio-Medical Canada Inc. distributes natural health supplements in North America and Asia. More Details
Imperfect balance sheet with weak fundamentals.
Share Price & News
How has Eastwood Bio-Medical Canada's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EBM is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: EBM's weekly volatility has decreased from 19% to 11% over the past year.
7 Day Return
1 Year Return
Return vs Industry: EBM underperformed the Canadian Pharmaceuticals industry which returned 23.2% over the past year.
Return vs Market: EBM exceeded the Canadian Market which returned 0.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Eastwood Bio-Medical Canada's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 months ago | Simply Wall StWe're Hopeful That Eastwood Bio-Medical Canada (CVE:EBM) Will Use Its Cash Wisely
8 months ago | Simply Wall StWe're Excited To See How Eastwood Bio-Medical Canada (CVE:EBM) Uses Its Cash Hoard To Grow
10 months ago | Simply Wall StThe Eastwood Bio-Medical Canada (CVE:EBM) Share Price Is Up 1892% And Shareholders Are Euphoric
Is Eastwood Bio-Medical Canada undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EBM's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EBM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EBM is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.
PE vs Market: EBM is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EBM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EBM is overvalued based on its PB Ratio (214.5x) compared to the CA Pharmaceuticals industry average (1.6x).
How is Eastwood Bio-Medical Canada forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Eastwood Bio-Medical Canada has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of EBM’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Eastwood Bio-Medical Canada competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Eastwood Bio-Medical Canada performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EBM is currently unprofitable.
Growing Profit Margin: EBM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EBM is unprofitable, and losses have increased over the past 5 years at a rate of 19.3% per year.
Accelerating Growth: Unable to compare EBM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EBM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-45%).
Return on Equity
High ROE: EBM has a negative Return on Equity (-103.86%), as it is currently unprofitable.
How is Eastwood Bio-Medical Canada's financial position?
Financial Position Analysis
Short Term Liabilities: EBM's short term assets (CA$191.5K) do not cover its short term liabilities (CA$225.3K).
Long Term Liabilities: EBM's short term assets (CA$191.5K) exceed its long term liabilities (CA$40.0K).
Debt to Equity History and Analysis
Debt Level: EBM's debt to equity ratio (5.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if EBM's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EBM has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: EBM has less than a year of cash runway if free cash flow continues to reduce at historical rates of 37.3% each year
What is Eastwood Bio-Medical Canada current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EBM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EBM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EBM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EBM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EBM's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. Youngsoo Kim serves as Chief Executive Officer of Eastwood Bio-Medical Canada Inc. since September 2020. He serves as the Chief Executive Officer and Owner of Eastwood Bio-Medical Research Inc. Dr. You...
|Independent Director||7.33yrs||no data||no data|
|Independent Director||7.33yrs||no data||0.0058% |
Experienced Board: EBM's board of directors are considered experienced (7.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Eastwood Bio-Medical Canada Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Eastwood Bio-Medical Canada Inc.
- Ticker: EBM
- Exchange: TSXV
- Founded: 2010
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$157.749m
- Shares outstanding: 68.89m
- Website: https://www.eleotin.ca
Number of Employees
- Eastwood Bio-Medical Canada Inc.
- 4871 Shell Road
- Unit 1130
- British Columbia
- V6X 3Z6
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|EBM||TSXV (TSX Venture Exchange)||Yes||Common Shares||CA||CAD||Sep 2014|
|EWOO.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Sep 2014|
Eastwood Bio-Medical Canada Inc. distributes natural health supplements in North America and Asia. The company distributes Eleotin products and related products. Its Eleotin brand of products provides natu...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/29 00:38|
|End of Day Share Price||2020/11/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.